ABSTRACT
The optimal chemoradiation regimen for patients with locally advanced non–small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a “one size fits all” approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation.
Footnotes
Dr. Videtic reported that he has no financial relationships that pose a potential conflict of interest with this article.
- © 2012 The Cleveland Clinic Foundation. All Rights Reserved.
View Abstract
